Afficher la notice abrégée

dc.creatorBamias, A.en
dc.creatorKaradimou, A.en
dc.creatorLampaki, S.en
dc.creatorAravantinos, G.en
dc.creatorXanthakis, I.en
dc.creatorPapandreou, C.en
dc.creatorLainakis, G.en
dc.creatorZagouri, F.en
dc.creatorSoupos, N.en
dc.creatorKostouros, E.en
dc.creatorSamantas, E.en
dc.creatorHatzimouratidis, C.en
dc.creatorKonstantinidis, C.en
dc.creatorDeliveliotis, C.en
dc.creatorPectasides, D. G.en
dc.creatorFountzilas, G.en
dc.creatorDimopoulos, M. A.en
dc.creatorHellenic Cooperative Oncology, Grpen
dc.date.accessioned2015-11-23T10:23:32Z
dc.date.available2015-11-23T10:23:32Z
dc.date.issued2011
dc.identifier.issn0732-183X
dc.identifier.urihttp://hdl.handle.net/11615/26136
dc.sourceJournal of Clinical Oncologyen
dc.source.uri<Go to ISI>://WOS:000208880300552
dc.subjectOncologyen
dc.titleProspective, randomized phase III study comparing two intensified regimens (methotrexate/vinblastine/doxorubicin hydrochloride/cisplatin MVAC versus gemcitabine/cisplatin) in patients with inoperable or recurrent urothelial canceren
dc.typejournalArticleen


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée